Publication & Citation Trends
Most Cited Works
Publications
497 total
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial PDF
Cited by 594
OpenAlex
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2 PDF
Cited by 246
OpenAlex
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 PDF
Cited by 565
OpenAlex
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis PDF
Cited by 514
OpenAlex
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer PDF
Cited by 2,808
OpenAlex
Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers
Cited by 562
OpenAlex
One-step Nucleic Acid Amplification for Intraoperative Detection of Lymph Node Metastasis in Breast Cancer Patients
Cited by 442
OpenAlex
Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells PDF
Cited by 232
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(144)
Estrogen and related hormone effects
(93)
Cancer Treatment and Pharmacology
(77)
HER2/EGFR in Cancer Research
(66)
Breast Lesions and Carcinomas
(60)
Frequent Co-Authors
Affiliations
Nihon University
Osaka Gakuin University
Roche (Switzerland)
Showa University
Novartis (Switzerland)